News

Efzofitimod, an experimental treatment for pulmonary sarcoidosis that’s set to begin Phase 3 clinical testing later this year, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). This designation is designed to speed up the development and review of investigational treatments that aim…

People with sarcoidosis in three of the hardest hit English-speaking cities during the initial stages of the COVID-19 pandemic — London, New Orleans, and New York — reported considerable disruptions in healthcare, a survey study has found. Patients also had concerns for their own survival and believed that they were…

Temple Lung Center at Temple Health in Philadelphia has become a founding member of the Foundation for Sarcoidosis Research (FSR) Global Sarcoidosis Clinic Alliance, a group of clinics and hospitals around the world that aims to improve the lives of sarcoidosis patients through care and research advancement. “Sarcoidosis is…

The Foundation for Sarcoidosis Research (FSR) has hosted a virtual session attended by people with pulmonary sarcoidosis and representatives from the U.S. Food and Drug Administration (FDA). FDA Patient Listening Sessions are small, informal, non-public meetings that discuss medical conditions from a patient’s perspective. The sessions seek to…

Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…

After the success of its virtual event last year, the Foundation for Sarcoidosis Research (FSR) is gearing up to once again host an online summit for all those impacted by sarcoidosis. The “Third Annual Global Virtual Patient Summit: Unveiling Possibilities” is set for July 30–31. Billed as the…

The Foundation for Sarcoidosis Research (FSR) has launched the FSR Global Sarcoidosis Clinic Alliance, a hub of clinics and hospitals around the world to advance care and research in sarcoidosis. Through engagement and education of both patients and clinicians, the initiative seeks to improve the lives of people with…

XTMAB-16, Xentria‘s investigational antibody-based therapy for treating sarcoidosis, was able to reduce the formation of granulomas — the abnormal clumps of immune cells that mark the disease — in a patient-derived cell model of granuloma, the company reported. The data were presented in a poster titled “XTMAB-16…

The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…

Children living in the same household with adults who work in mineral dust-releasing jobs may have an increased risk of developing sarcoidosis, according to a small study. The findings suggest that indirect exposure to potentially harmful minerals — and specifically, inhaled mineral particles — through co-habitation with adults working…